Skip to content

Severe Dry Eye Treatment with Autologous Platelet-Rich Plasma

Severe Dry Eye Treatment with Autologous Platelet-Rich Plasma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009161
Enrollment
Unknown
Registered
2016-09-05
Start date
2016-09-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Interventions

Treatment Group:platelet-rich plasma was given topically as eyedrops, 3 times a day, every time a drop, 28 days
Control group:artificial tears was given topically as eyedrops, 3 times a day, every time a drop, 28 days

Sponsors

The Ninth People's Hospital of Chongqing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: A previous diagnosis of severe dry eye; aged 18-60 years; symptom duration more than 6 months; conventional treatment with poor or no response; without any other treatment more than 2 weeks; all patients signed an informed consent before beginning therapy.

Exclusion criteria

Exclusion criteria: Exclude severe systemic disease and psychiatric patients; complicated with other eye diseases; wear contact lens;slight to moderate dry eye; Use other treatment within 2 weeks;did not accord with the Inclusion criteria; unwilling to accept this therapy.

Design outcomes

Primary

MeasureTime frame
BUT;Schirmer Test;Corneal staining scores;Dry eye symptom;

Countries

China

Contacts

Public ContactCai Mingming

The Ninth People's Hospital of Chongqing

mm198222@126.com+86 15696107998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026